Charles River Laboratories International, Inc. (NYSE:CRL) Receives $214.00 Average Price Target from Brokerages

Shares of Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) have been given a consensus rating of "Reduce" by the fifteen ratings firms that are presently covering the stock, MarketBeat.com reports. Three investment analysts have rated the stock with a sell rating, ten have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $214.00.

A number of research analysts have commented on the company. Citigroup cut Charles River Laboratories International from a "neutral" rating to a "sell" rating and reduced their price objective for the stock from $215.00 to $175.00 in a research note on Tuesday, October 1st. CLSA cut Charles River Laboratories International from a "hold" rating to an "underperform" rating and set a $164.00 price target for the company. in a report on Monday, November 18th. UBS Group lifted their price objective on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. TD Cowen upped their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a "hold" rating in a research note on Monday, November 11th. Finally, Evercore ISI raised their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the company an "in-line" rating in a report on Thursday, November 7th.

Insider Activity at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm's stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now directly owns 12,386 shares in the company, valued at approximately $2,676,862.32. This trade represents a 34.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.30% of the stock is owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Several hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. increased its holdings in shares of Charles River Laboratories International by 3.6% in the 3rd quarter. Principal Financial Group Inc. now owns 60,501 shares of the medical research company's stock worth $11,917,000 after acquiring an additional 2,126 shares during the period. Lord Abbett & CO. LLC increased its stake in shares of Charles River Laboratories International by 5.8% in the third quarter. Lord Abbett & CO. LLC now owns 108,715 shares of the medical research company's stock valued at $21,413,000 after purchasing an additional 5,959 shares during the period. Tidal Investments LLC raised its holdings in shares of Charles River Laboratories International by 37.8% during the third quarter. Tidal Investments LLC now owns 8,452 shares of the medical research company's stock valued at $1,665,000 after buying an additional 2,319 shares during the last quarter. Wilmington Savings Fund Society FSB acquired a new position in shares of Charles River Laboratories International during the third quarter worth approximately $59,000. Finally, Virtu Financial LLC bought a new position in Charles River Laboratories International in the 3rd quarter worth approximately $601,000. Institutional investors own 98.91% of the company's stock.

Charles River Laboratories International Trading Down 0.6 %

Shares of NYSE CRL traded down $1.01 during midday trading on Thursday, hitting $182.15. The stock had a trading volume of 624,229 shares, compared to its average volume of 617,212. The company has a quick ratio of 1.14, a current ratio of 1.48 and a debt-to-equity ratio of 0.61. Charles River Laboratories International has a 1-year low of $176.48 and a 1-year high of $275.00. The company has a market capitalization of $9.31 billion, a price-to-earnings ratio of 22.80, a PEG ratio of 5.00 and a beta of 1.38. The company has a fifty day moving average price of $194.14 and a 200 day moving average price of $202.40.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period in the previous year, the firm earned $2.72 earnings per share. Charles River Laboratories International's revenue for the quarter was down 1.6% on a year-over-year basis. On average, analysts predict that Charles River Laboratories International will post 10.18 earnings per share for the current year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).